;&
ensp; 五、会计估计和会计报表编制方法··········69 二、
公开引进战略投资者的确定·······················13 第三章 公司历史沿革、公司知识产权·····························27 三、
程序及评选办法········· 54 一、公司的新证书····························29 四、公司主要资产·····························27 二、重庆康卫概况····························· 6 二、
主要高管人员简历···························66 三、公司研发况·····························25 五、本次增资的定价及依据·························12 五、
公司原有股东增资···························39 二、幽门螺杆疫苗产业化初步时间安排·················· 108 第十二章 募集资金运用及项目财务评价··············· 110 一、市场风险······························ 121 六、江北区公司注册流程高级管理人员持有公司出资的况··············68 第九章 公司财务会计信息····················· 69 一、高级管理人员基本况·················66 二、
公司研发的幽门螺杆疫苗况·····················33 六、
产业化进展滞后风险························· 120 三、公开引进战略投资者的评选办法·····················65 第八章 董事、
实施募集资金运用项目的可行、岳兴长石化股份有限公司重庆康卫生物科技有限公司公开引进战略投资者说明书岳兴长石化股份有限公司重庆康卫生物科技有限公司公开引进战略投资者说明书查看PDF公告岳兴长石化股份有限公司重庆康卫生物科技有限公司公开引进战略投资者说明书 1 重庆康卫生物科技有限公司 公开引进战略投资者说明书 二〇〇九年八月重庆康卫生物科技有限公司 公开引进战略投资者说明书 2 目录 第一章 释义···························· 4 第二章 概览···························· 6 一、本次增资动因····························· 6 三、管理风险······························ 122三峡广场公司增资 股东股权冻结或质押况························23 第四章 公司基本况······················· 24 一、公司主要财务指标···························25 第五章 公司主要资产及研发的疫苗况··············· 27 一、公司经营况·····························24 四、本次增资的定价及依据·························51 七、
公司人员况·····························24 三、产业化实施风险··························· 120 四、公司未来发展战略·························· 103 二、公司历史沿革·····························14 二、 公司理结构风险·························· 120 二、 专家评审小组的人员及构成·······················65重庆康卫生物科技有限公司 公开引进战略投资者说明书 3 四、公开引进战略投资者的程序·······················64 三、高级管理人员················· 66 一、
公司的事项····························89 四、向公开引进的战略投资者增资······················47 四、监事、我国幽门螺杆疫苗市场前景······················94 第十一章 公司未来发展规划及产品产业化实施方案·········· 103 一、
公司本次增资实际募集资金金额·····················51 六、董事、现任董事、
本次增资前持有公司5%以上出资法人股东况介绍·············22 三、 公司实施励方案后增加的注册资本···················44 三、幽门螺杆感染的流行学况·····················90 二、公司税项·······························89   第十章 我国幽门螺杆疫苗行业市场况·············· 90 一、董事、 公司经审计的会计报表·························85 三、监事、公开引进战略投资者的条件·······················54 二、
监事、
实施本次增资方案的前提条件······················53 第七章 公开引进战略投资者的条件、 公司目前选用的会计政策、实施本次增资方案的附加条件······················49 五、本次增资方案简介··························· 7 四、与公司产品相关的专利况·······················37 第六章 公司本次增资方案····················· 39 一、公司基本况简介···························24 二、产品产业化实施方案························· 105 三、公司实施本次增资的前提条件······················13   六、必要及紧迫············ 110 三、高级管理人员的定协议安排················67 四、本次增资募集资金投向························ 110 二、主要股东况················ 14 一、募集资金运用项目财务评价······················ 111 第十三章 风险因素························ 120 一、
